No abstract available
MeSH terms
-
Alphapapillomavirus*
-
Cancer Vaccines* / administration & dosage
-
Cancer Vaccines* / adverse effects
-
Cancer Vaccines* / immunology
-
Condylomata Acuminata / prevention & control
-
Condylomata Acuminata / virology
-
Cost of Illness*
-
Esophageal Neoplasms / prevention & control
-
Esophageal Neoplasms / virology
-
Female
-
Genital Neoplasms, Female / prevention & control
-
Genital Neoplasms, Female / virology
-
Genital Neoplasms, Male / prevention & control
-
Genital Neoplasms, Male / virology
-
Global Health
-
Health Care Costs*
-
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
-
Humans
-
Hungary / epidemiology
-
Male
-
Mass Vaccination
-
Models, Theoretical
-
Neoplasms / economics
-
Neoplasms / epidemiology
-
Neoplasms / immunology
-
Neoplasms / prevention & control*
-
Neoplasms / virology*
-
Oropharyngeal Neoplasms / prevention & control
-
Oropharyngeal Neoplasms / virology
-
Papillomavirus Infections / complications*
-
Papillomavirus Infections / economics
-
Papillomavirus Infections / epidemiology
-
Papillomavirus Infections / immunology
-
Papillomavirus Infections / prevention & control*
-
Papillomavirus Infections / virology
-
Papillomavirus Vaccines* / administration & dosage
-
Papillomavirus Vaccines* / adverse effects
-
Papillomavirus Vaccines* / immunology
-
Primary Prevention
-
Public Health*
-
Respiratory Tract Infections / prevention & control
-
Respiratory Tract Infections / virology
-
Secondary Prevention
-
Vaginal Smears
Substances
-
Cancer Vaccines
-
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
-
Papillomavirus Vaccines
-
human papillomavirus vaccine, L1 type 16, 18
Supplementary concepts
-
Recurrent respiratory papillomatosis